United Therapeutics Corporation (UTHR) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Total Revenue Chart for United Therapeutics Corporation

United Therapeutics Corporation (UTHR) revenue for FY2025 was USD 3.2B, a 10.6% change from FY2024. United Therapeutics Corporation's revenue grew from USD 100.0K in 1998 to USD 3.2B in 2025 (3182600.0% over 27 years). Earnings per share grew from USD 0.33 in 2004 to USD 15.00 in 2022 (4433.2%). Revenue compound annual growth rate: 5-year CAGR of 16.5%, 10-year CAGR of 8.1%, 20-year CAGR of 18.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.